Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis.
| Autor: | Ivaturi V; Pumas-AI, Baltimore, Maryland., Gobburu J; Pumas-AI, Baltimore, Maryland., Leslie B; Otsuka Pharmaceutical Development & Commercialization (OPDC), Inc., Princeton, New Jersey., Wang X; Otsuka Pharmaceutical Development & Commercialization (OPDC), Inc., Princeton, New Jersey., Jadhav P; MDCI Biosciences LLC, Philadelphia, Pennsylvania. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Kidney360 [Kidney360] 2024 Jul 01; Vol. 5 (7), pp. 996-1001. Date of Electronic Publication: 2024 Jun 10. |
| DOI: | 10.34067/KID.0000000000000485 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|